We are live on ! Find out more
PCRX icon

Pacira BioSciences
PCRX

180 hedge funds and large institutions have $1.35B invested in Pacira BioSciences in 2016 Q3 according to their latest regulatory filings, with 36 funds opening new positions, 66 increasing their positions, 51 reducing their positions, and 37 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more funds holding in top 10

Funds holding in top 10: 3 → 5 (+2)

49% more call options, than puts

Call options by funds: $24.8M | Put options by funds: $16.6M

29% more repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 51

2% less capital invested

Capital invested by funds: $1.38B → $1.35B (-$28.8M)

3% less first-time investments, than exits

New positions opened: 36 | Existing positions closed: 37

2% less funds holding

Funds holding: 183 → 180 (-3)

Holders
180
Holders Change
-3
Holders Change %
-1.64%
% of All Funds
4.8%
Holding in Top 10
5
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+66.67%
% of All Funds
0.13%
New
36
Increased
66
Reduced
51
Closed
37
Calls
$24.8M
Puts
$16.6M
Net Calls
+$8.21M
Net Calls Change
+$16.3M

Top Buyers

Rank Fund Capital Flow
1
Macquarie Group
Macquarie Group
Australia
+$39.8M
2
Citadel Advisors
Citadel Advisors
Florida
+$30.2M
3
HM
HealthCor Management
New York
+$19.4M
4
GIM
Granahan Investment Management
Massachusetts
+$18.1M
5
Deutsche Bank
Deutsche Bank
Germany
+$13.2M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$49.6M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$41.3M
3
Millennium Management
Millennium Management
New York
-$24.3M
4
GGHC
Gilder Gagnon Howe & Co
New York
-$21.6M
5
HCM
Hoplite Capital Management
New York
-$20.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
Loomis, Sayles & Company
176
Loomis, Sayles & Company
Massachusetts
$2K – – –
ADL
177
Asset Dedication LLC
California
$2K +$1.72K +44 New
PG
178
Patten Group
Tennessee
$1.83K – – –
CHP
179
Cable Hill Partners
Oregon
$1K +$862 +22 New
GWM
180
Geneos Wealth Management
Colorado
$1K +$1.8K +46 New
HCM
181
Hoplite Capital Management
New York
– -$20.4M -605,720 Closed
MCM
182
Marsico Capital Management
Colorado
– -$17.9M -531,944 Closed
Point72 Asset Management
183
Point72 Asset Management
Connecticut
– -$9.49M -281,236 Closed
EAM
184
EverPoint Asset Management
Connecticut
– -$8.94M -265,000 Closed
KCM
185
Kingdon Capital Management
New York
– -$7.13M -211,500 Closed
SO
186
STRS Ohio
Ohio
– -$5.4M -160,000 Closed
GTC
187
Ghost Tree Capital
New York
– -$4.05M -120,000 Closed
DM
188
Deerfield Management
New York
– -$1.69M -50,000 Closed
ACM
189
Asymmetry Capital Management
California
– -$1.41M -41,707 Closed
SSA
190
Schonfeld Strategic Advisors
New York
– -$1.36M -40,447 Closed
TC
191
TFS Capital
Pennsylvania
– -$1.32M -39,189 Closed
GCP
192
GSA Capital Partners
United Kingdom
– -$1.01M -29,900 Closed
OAM
193
Oxford Asset Management
United Kingdom
– -$980K -29,061 Closed
LM
194
Litespeed Management
New York
– -$843K -25,000 Closed
VKH
195
Virtu KCG Holdings
New York
– -$805K -23,875 Closed
AL
196
Airain Ltd
Guernsey
– -$538K -15,946 Closed
PP
197
Paloma Partners
Connecticut
– -$470K -13,944 Closed
TSS
198
Two Sigma Securities
New York
– -$452K -13,392 Closed
NIT
199
NumerixS Investment Technologies
British Columbia, Canada
– -$352K -10,423 Closed
DS
200
DRW Securities
Illinois
– -$341K -10,100 Closed
5 6 7
8
9

PCRX Hedge Fund Activity: Q3 2016 in Review

180 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q3 2016, worth a combined $1.35B — down 2.1% from $1.38B a quarter earlier.

Sellers outnumbered buyers: 37 funds closed out of PCRX and 36 opened new positions — a net loss of 1 holder — while 51 trimmed existing stakes and 66 added.

The largest buyer was Macquarie Group, adding an estimated $39.8M. The largest seller was Fidelity Investments, cutting an estimated $49.6M.

  • 180 institutional investors held Pacira BioSciences (PCRX) as of Q3 2016, down from 183 in Q2 2016.
  • Funds reported $1.35B of Pacira BioSciences stock for Q3 2016, down 2.1% quarter-over-quarter.
  • 36 funds opened new Pacira BioSciences positions in Q3 2016 and 37 closed out, a net change of -1 holder.
  • The largest Pacira BioSciences buyer in Q3 2016 was Macquarie Group, an estimated $39.8M added.
  • The largest Pacira BioSciences seller in Q3 2016 was Fidelity Investments, an estimated $49.6M sold.

Based on aggregated 13F filings for Q3 2016.